Earnings Update
Rossari Biotech Reports Highest-Ever Quarterly Revenue; Q4 PAT Jumps 34% YoY
NSE
rossari
BSE
543213
Rossari Biotech delivered its highest-ever quarterly performance in Q4 FY26, with revenue up 18% YoY and PAT up 34% YoY, supported by strong growth across all business segments
PRICE-SENSITIVE TRIGGER
Event: Q4 FY26 & FY26 Financial Results Announcement
Type: Earnings Update
Impact: Positive
Immediate Effect: Strong profitability growth despite margin pressure
Key Metrics:
Key Metrics (Q4 FY26)
- Revenue → ₹684.9 Cr (+18% YoY)
- EBITDA → ₹77.3 Cr (+11% YoY)
- PAT → ₹46.0 Cr (+34% YoY)
- EBITDA Margin → 11.3% (vs 12.0%)
Key Metrics (FY26)
- Revenue → ₹2,396.4 Cr (+15% YoY)
- EBITDA → ₹286.0 Cr (+8% YoY)
- PAT → ₹149.2 Cr (+9% YoY)
- EBITDA Margin → 11.9% (vs 12.7%)
Highlight:
- Highest-ever quarterly revenue and EBITDA
What Happened ?
Rossari Biotech announced its Q4 and FY26 results, showcasing strong revenue and profit growth, driven by performance across HPPC, TSC, and AHN segments, despite margin pressure from input costs.
key highlights
Segment Performance:
- All segments (HPPC, TSC, AHN):
- Delivered double-digit growth
- Strong diversified portfolio performance
Margin Analysis:
- EBITDA margins declined:
- Due to raw material cost pressure
- Lag in passing cost inflation
- Company focusing on:
- Pricing actions
- Product mix improvement
- Operating leverage
Operational Development:
- Ethoxylation capacity expanded:
- +15,000 MTPA added
- Total capacity → 66,000 MTPA
Strategic Initiative:
- Capex plans:
- Rephased over next 2 years
- R&D expansion:
- New facility in Navi Mumbai
- Focus on:
- Innovation-led growth
Corporate Actions:
- Dividend:
- ₹0.50 per share recommended
- Board Changes:
- Appointment of Independent Director
Risk Analysis
Key Risks
- Declining EBITDA margins
- Raw material cost volatility
- Pricing pass-through delays
- Capex execution risks
Worst Case Scenario
- Revenue growth continues but profitability weakens due to margin compression
Risk Level: Medium
Company Commentary
- Achieved highest-ever quarterly revenue and EBITDA
- Strong double-digit growth across all business segments
- Margins impacted by raw material inflation and cost lag
- Focus on pricing, product mix and operating leverage
- Expanding manufacturing capacity and R&D capabilities
Official Exchange Filing: Rossari Biotech Limited